<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04658758</url>
  </required_header>
  <id_info>
    <org_study_id>APHP201085</org_study_id>
    <secondary_id>2020-A02319-30</secondary_id>
    <nct_id>NCT04658758</nct_id>
  </id_info>
  <brief_title>The Incidence and Risk of Vein Infusion Phlebitis After Intravenous Infusion of Proton Pump Inhibitors</brief_title>
  <acronym>VeinIPP</acronym>
  <official_title>Risk Assessment and Incidence of Vein Infusion Phlebitis After Intravenous Infusion of Proton Pump Inhibitors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Intermittent or continuous proton pump inhibitor (PPI) therapy are recommended for high-risk&#xD;
      bleeding ulcers according to the French Society of Gastroenterology. The prevalence of&#xD;
      incidence of vein infusion phlebitis after PPI intravenous infusion is high in geriatric&#xD;
      acute ward (about 10% of severe vein infusion phlebitis).&#xD;
&#xD;
      The primary of objective of the study is to determinate the prevalence of vein infusion&#xD;
      phlebitis after PPI intravenous infusion in aging people.&#xD;
&#xD;
      The secondary of objective of the study if to determinate the factors of risk of vein&#xD;
      infusion phlebitis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter observational study. 5 centers will participate to the study. Aging&#xD;
      patients undergoing PPI intravenous infusion therapy will be proposed to be enrolled in the&#xD;
      study. Paramedical observation will be performed during 5 days for each enrolled patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 4, 2020</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Occurence of infusion phlebitis</measure>
    <time_frame>at day-5</time_frame>
    <description>The Visual Infusion Phlebitis Scale will be used to define.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Factors of risk of vein infusion phlebitis</measure>
    <time_frame>Throughout of the study, an average of 1 year</time_frame>
    <description>To determinate risk factors for vein infusion phlebitis.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Vein Infusion Phlebitis</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Hospitalized patients aged &gt; 70 years.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients aged &gt; 70 years;&#xD;
&#xD;
          -  Undergo intravenous continuous or intermittent proton pump inhibitor therapy;&#xD;
&#xD;
          -  Patients being informed and not opposed to the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Existing vein infusion phlebitis before the PPI infusion by intravenous route;&#xD;
&#xD;
          -  Under guardianship or curators;&#xD;
&#xD;
          -  Covered by french AME health system.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>70 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marion PEPIN, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Geriatric Department, Ambroise Paré Hospital, APHP</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marion PEPIN, MD, PhD</last_name>
    <phone>+33 (0)1 49 09 45 51</phone>
    <email>marion.pepin@aphp.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Geriatric Department, Ambroise Paré Hospital, APHP</name>
      <address>
        <city>Boulogne-Billancourt</city>
        <zip>92100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>November 30, 2020</study_first_submitted>
  <study_first_submitted_qc>December 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 8, 2020</study_first_posted>
  <last_update_submitted>December 11, 2020</last_update_submitted>
  <last_update_submitted_qc>December 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>vein infusion phlebitis</keyword>
  <keyword>proton pump inhibitor therapy</keyword>
  <keyword>intravenous infusion</keyword>
  <keyword>ulcer bleeding</keyword>
  <keyword>aging</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Phlebitis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

